Evidence map›Paper›PMID 21253697›Full record

ArticleDiabetologia2011

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.

R Kodera, K Shikata, H U Kataoka, T Takatsuka, S Miyamoto, M Sasaki, N Kajitani, S Nishishita, K Sarai, D Hirota and 3 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01847313 (Phase 3 Study of the Effect of Glucagon-like-peptide 1), which is not on this map. Cited by 197 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
197citing papers in PubMed, 2 pooled it
17.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01847313 phase3completedstarted 2013, after this paper: background citation

Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease

Ran2013Enrolled20Registered outcomes6Posted comparisons0ConditionsDiabetic Kidney DiseaseArmsliraglutide
PMID 20622169PMID 20002084PMID 22691169PMID 21744074PMID 18487229PMID 19238145PMID 19585513PMID 17167242PMID 23173142PMID 14675042PMID 15664230PMID 16177002other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

197 citing papers in PubMed, 2 syntheses or guidelines pooled it, 378 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists.International journal of molecular sciences · 2025
    Review
  20. Review

137 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

R KoderaDepartment of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
K Shikata
H U Kataoka
T Takatsuka
S Miyamoto
M Sasaki
N Kajitani
S Nishishita
K Sarai
D Hirota
C Sato
D Ogawa
H Makino
Okayama University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisGlucagon-like peptide-1 (GLP-1) has various extra-pancreatic actions, in addition to its enhancement of insulin secretion from pancreatic beta cells. The GLP-1 receptor is produced in kidney tissue. However, the direct effect of GLP-1 on diabetic nephropathy remains unclear. Here we demonstrate that a GLP-1 receptor agonist, exendin-4, exerts renoprotective effects through its anti-inflammatory action via the GLP-1 receptor without lowering blood glucose.

methodsWe administered exendin-4 at 10 μg/kg body weight daily for 8 weeks to a streptozotocin-induced rat model of type 1 diabetes and evaluated their urinary albumin excretion, metabolic data, histology and morphometry. We also examined the direct effects of exendin-4 on glomerular endothelial cells and macrophages in vitro.

resultsExendin-4 ameliorated albuminuria, glomerular hyperfiltration, glomerular hypertrophy and mesangial matrix expansion in the diabetic rats without changing blood pressure or body weight. Exendin-4 also prevented macrophage infiltration, and decreased protein levels of intercellular adhesion molecule-1 (ICAM-1) and type IV collagen, as well as decreasing oxidative stress and nuclear factor-κB activation in kidney tissue. In addition, we found that the GLP-1 receptor was produced on monocytes/macrophages and glomerular endothelial cells. We demonstrated that in vitro exendin-4 acted directly on the GLP-1 receptor, and attenuated release of pro-inflammatory cytokines from macrophages and ICAM-1 production on glomerular endothelial cells. CONCLUSIONS/

interpretationThese results indicate that GLP-1 receptor agonists may prevent disease progression in the early stage of diabetic nephropathy through direct effects on the GLP-1 receptor in kidney tissue.

Indexed as

AnimalsBlood GlucoseBlotting, WesternCell LineCell Line, TumorCollagen Type IVDiabetes Mellitus, Type 1Diabetic NephropathiesExenatideFluorescent Antibody TechniqueGlucagon-Like Peptide-1 ReceptorHumansIntercellular Adhesion Molecule-1MaleNF-kappa BPeptidesBlood GlucoseCollagen Type IVExenatideGLP1R protein, humanGlp1r protein, ratGlucagon-Like Peptide-1 ReceptorIntercellular Adhesion Molecule-1NF-kappa BPeptidesReceptors, GlucagonTumor Necrosis Factor-alphaVenoms

Identifiers

PMID21253697
OpenAlexW2090360729

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.